Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu177-PSMA for refractory PSMA-avid papillary thyroid cancer
IRCT20230803059015N1Phase 2Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Aug 2023
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lutetium lu 177 vipivotide tetraxetan in papillary thyroid cancer (PTC), sponsored by Shiraz University of Medical Sciences. Primary endpoints: Baseline serum thyroglobulin, Post-therapy thyroglobulin level and 2 more. Started Aug 2023; status: completed.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
papillary thyroid cancer (PTC)
Beyond the preview
Go deeper on IRCT20230803059015N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230803059015N1.